Early Life and Education
Ren Jinsheng was born in 1963. He graduated from Nanjing University of Chinese Medicine in 1982 with a diploma in Chinese Materia Medica. He later obtained a Master's degree in Business Administration from Nanjing Normal University in 1996. After graduating, he worked at Qidong Pharmaceutical Factory before venturing into entrepreneurship.
Rise to Success
Ren Jinsheng's entrepreneurial journey began in March 1995 when he founded Simcere Pharmaceutical Group. Starting with limited capital, Simcere initially focused on distribution. Ren Jinsheng has been the Chairman and CEO since 2004. Under his leadership, Simcere transitioned into a pharmaceutical manufacturing company. Simcere was listed on the NYSE in 2007 and later listed on the Hong Kong Stock Exchange in 2020. In 2025, the Ren Jinsheng family was ranked #382 on the Hurun Rich List, with a fortune of 17 billion yuan, which skyrocketed by 127% compared to the previous year. In December 2025, Simcere Zaiming signed an exclusive licensing agreement with Ipsen Pharma SAS for a potential $1.06 billion.
Key Business Strategies
Ren Jinsheng strategically transformed Simcere from a generics-focused company to an innovation and R&D-driven pharmaceutical company. The company focuses on neuroscience, oncology, autoimmune, and anti-infection therapies. This strategic shift included building an in-house R&D team. He also emphasized attracting top research talent to realize Simcere's ambitions.
Philanthropy
While specific philanthropy amounts are not readily available, Ren Jinsheng's leadership reflects a commitment to improving healthcare. The company's mission, “for patients, for life,” highlights a focus on patient well-being.
